Floatz logo

VOLITINIB

Locally Advanced Papillary Renal Cell Carcinoma

AstraZenecaSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Locally Advanced Papillary Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
First Affiliated Hospital, Sun Yat-Sen University
Phase 3BB
Pembrolizumab
First Affiliated Hospital, Sun Yat-Sen University
Phase 3BB
Bms-907351
National Cancer Institute (NCI)
Phase 2BB
Bms-907351
National Cancer Institute (NCI)
Phase 2BB

View all 37 →

Same molecule, other indications

VOLITINIB is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →